About us Editorial board Search Ahead of print Current issue Archives Instructions Subscribe Contacts Login 
Home Print this page Email this page Users Online: 254
Year : 2018  |  Volume : 5  |  Issue : 1  |  Page : 15-20

Benefits of anti-vascular endothelial growth factor therapy for diabetic macular edema with and without vitreomacular adhesions

1 Department of Ophthalmology, Research Institute of Ophthalmology, Giza, Egypt
2 Department of Ophthalmology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Correspondence Address:
Dr. Yasmine Salah Salem
Research Institute of Ophthalmology, Giza
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/erj.erj_2_18

Rights and Permissions

Purpose: We aimed to evaluate the effect of vitreomacular adhesion (VMA) in visual and anatomic outcomes in patients with diabetic macular edema (DME) after intravitreal injection of ranibizumab (Lucentis®). Patients and Methods: This was a prospective cohort study that included thirty eyes of DME patients, divided into two groups according to their spectral-domain-optical coherence tomography image analysis at the baseline visit to identify the presence (VMA+) or absence (VMA−) of VMA. Patients with any degree of vitreomacular traction were not included in this study. VMA was classified by the size of adhesion into either focal (<1500 mm) or broad (>1500 mm). All patients received monthly 0.5 mg of intravitreal ranibizumab injection for 6 months. Patients were observed monthly for a 6-month period and their best-corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded. The incidence of posterior vitreous detachment (PVD) was observed. Results: Compared with baseline, there was a significant decrease in CMT after 6 months by 151.46 ± 121.47 and 139.33 ± 144.23 μm in VMA+ and VMA− groups, respectively (P = 0.681). The mean average improvement in BCVA was 10.21 ± 6.33 and 6.68 ± 6.35 letters in the VMA+ and VMA− groups, respectively. The difference between the two groups was statistically significant (P = 0.007). At 6 months, among the 15 eyes of VMA+ at baseline, 4 eyes demonstrated PVD and 11 eyes showed no change in VMA status. Conclusion: Patients having DME with VMA may achieve higher visual gain with anti-vascular endothelial growth factor therapy. Presence of VMA should not preclude patients with DME from receiving anti-vascular endothelial growth factor therapy.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded58    
    Comments [Add]    

Recommend this journal